Tahir Amin, DipLP, co-founder and director of intellectual property of Initiative for Medicines, Access, and Knowledge, discusses reforming the patent system.
Transcript:
Are there some specific reforms in patents that you would like to see the United States implement to help encourage competition in drug pricing?
One of the key areas that I think needs to be improved upon is the standard of what is patentable. I feel the law has not kept up with the advances with how [research and development, R&D] is done, and how scientific knowledge has been accumulated over the last 50 years. Unfortunately, in order to get your patent, you’re judged by whether it’s novel, based on what’s known in the field, or if it is obvious to someone in the field.
The obviousness standard is not applied in the correct way. It’s almost as if techniques from 50 years ago are still not obvious to people, and I think the law hasn’t kept up.
One of things my organization and other organizations has talked about is bringing that standard up to where science is today, and we’ll find that a lot of things are obvious. Patents would not be granted so readily, and only the really high-end inventions would be. That’s where a lot of the focus needs to be on, unfortunately the court systems are in this old sort of thinking, “Oh it’s what it was 20 [or] 30 years ago.”
I think the other area is we need more public participation in the patent system, the public actor or patient group cannot challenge a case in court unless its infringing the actual product in question. Which means, therefore, only commercial actors have the right to challenge a patent. Which is why the Oil States case is important, because that forum allows any person—any public person or a group like ours can go in there without infringing. Getting rid of this would be catastrophic, because it means only the rich get to play in a rich playground.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
Dr Joseph Alvarnas Highlights the Current State of the Oncology Biosimilar Market
November 9th 2022Joseph Alvarnas, MD, vice president of government affairs at City of Hope and chief clinical adviser of AccessHope, explains what the recent FDA approvals of Stimufend and Vegzelma, 2 oncology biosimilars, says about the current state of the oncology biosimilar space.
Expert Opinion: What Factors Will Have the Greatest Impact on US Adoption of Humira Biosimilars?
April 12th 2022Jeffrey Casberg, vice president of pharmacy at IPD Analytics, weighs in on the factors he thinks will most affect market share among adalimumab biosimilars when they enter the US market in 2023.